Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era

Oakley, Fredrick D.; Desouki, Mohamed Mokhtar; Pemmaraju, Manideepthi; Gargano, Julia M.; Markowitz, Lauri E.; Steinau, Martin; Unger, Elizabeth R.; Zhu, Yuwei; Fadare, Oluwole; Griffin, Marie R.

doi:10.1016/j.amepre.2018.03.015

Cited by 10 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increasing HPV vaccination coverage coupled with our observed declines in AGWs among young females in the vaccine era suggest vaccine impact for preventing AGWs. These results complement a recent Tennessee study that reported declines in cervical intraepithelial neoplasia grade 2 or greater among young females aged 18–24 years, but not in older females during the same time period [25]. Further, our findings corroborate previous studies in the US [[26], [27], [28], [29]] and other countries [14,[30], [31], [32]] which have reported declines in AGWs among adolescents and young adults since the introduction of the HPV vaccine.…”

Section: Discussionsupporting

confidence: 88%

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

Shing

Hull

Zhu

et al. 2019

Papillomavirus Research

Self Cite

View full text Add to dashboard Cite

Introduction Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in Tennessee by assessing AGW trends among Tennessee Medicaid (TennCare) enrollees aged 15–39 years from 2006-2014. Methods Persons with incident AGWs were identified using diagnosis/pharmacy codes from TennCare billing claims. We calculated sex-specific annual AGW incidence by age group, race, and urbanicity; estimated annual percent changes (APCs) using log-linear models; and performed pairwise comparisons by race and urbanicity. Results AGW incidence decreased among females aged 15–19 (APC = −10.6; P < 0.01) and 20–24 years (APC = −3.9; P = 0.02). Overall trends were similar between Whites and Blacks, and between those living in metropolitan statistical areas (MSAs) and non-MSAs. Rates among males aged 15–19 years began decreasing after 2010. Among enrollees aged 25–39 years, rates increased or were stable. Conclusions Following introduction of the HPV vaccine in 2006, AGWs decreased among age groups most likely to be vaccinated. The change in trend among young males after 2010 suggests early herd effects. Our findings indicate vaccine effects and support the importance of improving adherence to current vaccination recommendations for preventing AGWs and other HPV-related diseases.

show abstract

Section: Discussionsupporting

confidence: 88%

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

Shing

Hull

Zhu

et al. 2019

Papillomavirus Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…1,[59][60][61] A recent evaluation of high-grade cervical pre-cancers in a surveillance site in Tennessee documented average annual decreases in CIN2+ of −24% in 18-20-year-olds and −10% in 21-24-year-olds in the HPV vaccine era. 62 Evidence for prevention of cervical cancer Early estimates of US national-level reduction in cervical cancer incidence were published in 2018 by Guo et al 63 That study compared cervical cancer rates between 2003-6 and 2011-14 for age groups for whom HPV vaccine has been recommended (15-24 years and 25-34 years of age). Relative to 2003-2006, cervical cancer rates were 29% lower in 2011-14 for 15-24-year-olds and 13% lower for 25-34 yearolds, with no differences observed in women aged 35 and older.…”

Section: Addressing Mythmentioning

confidence: 99%

Addressing HPV vaccine myths: practical information for healthcare providers

Bednarczyk

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Human papillomavirus (HPV) vaccine uptake consistently lags behind that of other adolescent vaccines. In 2017, uptake of a single HPV vaccine dose and HPV vaccine series completion was 66% and 49%, respectively, compared to uptake of tetanus, diphtheria, and acellular pertussis vaccine (89%) and quadrivalent meningococcal conjugate vaccine (85%). Reasons for not vaccinating adolescents again HPV are varied, and in many cases, are rooted in commonly spread myths and misperceptions about the vaccine. In this review, we address five key myths-HPV vaccination is not effective at preventing cancer; Pap smears are sufficient to prevent cervical cancer; HPV vaccination is not safe; HPV vaccination is not needed since most infections are naturally cleared by the immune system; 11-12 years of age is too young to vaccinate. For each myth, we summarize the scientific evidence refuting the myth and provide speaking prompts for healthcare professionals to communicate about HPV vaccination.

show abstract

“…(1,2) The nine-valent HPV vaccine (9vHPV) prevents infection from high-risk HPV types that cause 85% of cervical cancer cases. (3) Despite established safety and efficacy of the HPV vaccine, as well as growing evidence of its clinical effectiveness, (1,(4)(5)(6)(7)(8)(9) vaccine administration has lagged. Rates of series initiation and completion among adolescents aged 13-17 years remain low (68.1% and 51.1%, respectively).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of an Inpatient Postpartum Human Papillomavirus Immunization Program

Avni-Singer

Oliveira

Torres

et al. 2020

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Objective: To evaluate the result of an inpatient postpartum human papillomavirus (HPV) immunization pilot program in a diverse, low-income patient population from an urban, hospitalbased obstetrics and gynecology clinic. Methods:In this cohort study, we present results from the first two years of the inpatient postpartum HPV immunization program, in which vaccine-eligible postpartum women were identified and immunized during their hospital stay. The program was implemented following educational outreach with prenatal and postpartum clinicians and nurses. Associations between receipt of HPV vaccine as an inpatient and characteristics of patients, and likelihood of and missed opportunities for receiving a subsequent dose of HPV vaccine as an outpatient were determined using logistic regression, time-to-event analyses, chi-squared tests and student's t-tests.Results: From 04/11/2017 to 04/10/2019, 394 (59.2%) of 666 postpartum women were eligible for the inpatient postpartum HPV immunization program. The majority (265/394, 67.3%) received the IPP-HPV dose, 36/265 (13.6%) of whom completed the series with that dose. Among women due for additional doses after hospital discharge, those who received the inpatient dose were more likely to receive a subsequent outpatient dose (138/229) than were those who did not receive an inpatient dose (39/129; Hazard ratio: 2.51, 95% CI 1.76 to 3.58). On average, there were 30.7 fewer (95% CI 5.8-55.6, p<0.02) missed opportunities for subsequent outpatient doses for every 100 eligible visits among women who received the inpatient dose compared with women who did

show abstract

Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era

Cited by 10 publications

References 25 publications

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

Addressing HPV vaccine myths: practical information for healthcare providers

Evaluation of an Inpatient Postpartum Human Papillomavirus Immunization Program

Contact Info

Product

Resources

About